Denali Therapeutics (DNLI) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 28.6% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $2.49 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | NAMS |
|---|---|---|
| Share price | $18.67 | $21.26 |
| Market cap | $2.98B | $2.49B |
| 1-day change | -2.56% | -3.93% |
| YTD return | +16.05% | -36.92% |
| 1-year return | +28.59% | -31.29% |
| 5-year return | -57.95% | +126.05% |
| EPS (TTM) | $-2.84 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | $-512.54M | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $27.30 | $42.21 |
| 52-week low | $13.75 | $20.94 |
| Distance from 52-week high | -31.61% | -49.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.14% | +133.54% |
| Average volume | 1.61M | 1.35M |
| Shares outstanding | 159.85M | 116.90M |
| Employees | 503 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed NAMS by 59.9 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
DNLI vs NAMS FAQ
Which is bigger, Denali Therapeutics or NewAmsterdam Pharma N.V.?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $2.49B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, DNLI or NAMS?
DNLI returned +28.59% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and NewAmsterdam Pharma N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for NewAmsterdam Pharma N.V..